Creutzfeldt–Jakob disease

Chronic wasting disease has been detected in British Columbia deer, and we need to act now

Retrieved on: 
Friday, February 16, 2024

Since 1996, a deadly neurodegenerative disease of cervids (deer, elk, moose, caribou, reindeer) has been spreading across Canada.

Key Points: 
  • Since 1996, a deadly neurodegenerative disease of cervids (deer, elk, moose, caribou, reindeer) has been spreading across Canada.
  • On Jan. 31, 2024, chronic wasting disease (CWD) was detected for the first time in British Columbia in two deer.

Disease-causing proteins

  • The protein is similar to other normal proteins in the body, except it’s abnormally shaped.
  • The abnormal folding of these disease-causing prion proteins — which are found most abundantly in the brain — leads to brain damage that makes the brain appear like a sponge.
  • Other TSEs include Creutzfeldt-Jakob disease in people, bovine-spongiform encephalopathy (“mad cow disease”) in cows, and scrapie in sheep and goats.
  • This means that early detection and management is critical for reducing the impact of this disease.

British Columbia’s preparations

  • has established a surveillance program to detect CWD as soon as possible.
  • Our research suggests that a robust approach to such a difficult disease will require rapid, collective and collaborative action across sectors.
  • This approach must involve wildlife managers, hunters, local communities, First Nations and researchers to integrate a number of approaches.

Surveillance and management

  • Many CWD management programs rely on removing infected animals from the landscape.
  • While it is mandatory to submit the heads from hunted cervids in select management units in B.C., in most regions, submission is voluntary.
  • Hunters can participate in CWD management and surveillance by removing the head of the animal and submitting it to a local testing station or freezer for CWD testing.
  • The public can also participate in CWD surveillance and management by reporting signs of sick animals and vehicle collisions with cervids.
  • This is why testing cervids that have been killed by vehicles is also a critical component of CWD surveillance and management.

Curbing the spread

  • CWD can spread between animals through contact with bodily fluids.
  • Legal restrictions on carcass transport and the use of urine-based scents in hunting can also reduce the unintentional spread of CWD.
  • Research has shown that community-focused communication and engagement are essential for the success of CWD management efforts.
  • In the days ahead, fostering open dialogue and collaboration will be paramount towards an effective and sustainable effort against CWD.


Kaylee Byers is the Regional Deputy Director of the British Columbia Node of the Canadian Wildlife Health Cooperative and collaborates with the Wildlife Health Program, which leads Chronic Wasting Disease surveillance in British Columbia. Sarah Robinson does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

The tantalising scent of rain or freshly baked bread: why can certain smells transport us back in time?

Retrieved on: 
Wednesday, September 27, 2023

Simply by living among sawdust and woodchips, you learn to distinguish the different smells of wood.

Key Points: 
  • Simply by living among sawdust and woodchips, you learn to distinguish the different smells of wood.
  • Years after my father retired, I was walking through the underbelly of a hospital when, completely by chance, I stumbled upon the maintenance room.
  • Suddenly and unexpectedly, I was transported back to my native Toledo (in Spain), to my father’s carpentry workshop.

Smells that revive past emotions

    • The scent of freshly baked cakes or bread, the chlorine of a swimming pool in summer, a salty sea breeze, coffee, and rain are smells that cause our minds to recover memories and emotions that we thought long forgotten.
    • Memory is the brain’s ability to compile, store and recover information based on past experiences.
    • Numerous scientific studies have tried to discover how we can recover memories and sensations from the past through a particular smell.

A direct line to emotional memory

    • For this reason, a familiar smell activates the same areas of the brain as those related to emotional memory.
    • In fact, scent induced memories tend to be connected to past experiences with a greater emotional significance than other senses.

The loss of smell, a sign of neurological illness

    • Many of us experienced this first hand during the covid-19 pandemic, when millions of people lost their sense of smell.
    • Intriguingly, many disorders linked to a loss of smell are neurodegenerative, where one of the associated symptoms is memory loss.
    • LH, this reads as though all loss of smell ends up with Alzheimer’s, which i don’t think is what is meant, given the next paragraph.

Olfactory gymnastics to rehabilitate your memory?

    • Consequently, in recent years there has been interest in determining the therapeutic potential of scents to stimulate and rehabilitate memory in patients with neurological disorders.
    • Olfactory enrichment –smelling a range of different scents– can reverse loss of smell caused by an infection, craneal trauma, Parkinson’s and aging.
    • Obviously, more research is needed to definitively conclude that regular olfactory stimulation helps to protect the brain and prevent cognitive decline or impairment.

Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Tuesday, May 2, 2023

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at the 26th ASGCT Annual Meeting being held May 16-20, 2023, in-person in Los Angeles, CA and in a virtual format.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at the 26th ASGCT Annual Meeting being held May 16-20, 2023, in-person in Los Angeles, CA and in a virtual format.
  • Presentations will focus on the progression of Sangamo’s pre-clinical programs, including data from the prioritized neurology programs Nav1.7 and Prion, innovations in the epigenetic regulation platform and advances in AAV capsid engineering for delivery.
  • Additional presentations at the ASGCT Annual Meeting will showcase how Sangamo is advancing its proprietary zinc finger platform development efforts, including the use of zinc finger transcriptional regulators designed to reduce the expression of the Prion protein for the treatment of Creutzfeldt-Jakob disease.
  • Sangamo will also present data from its proprietary AAV capsid discovery platform SIFTER™, which enables the engineering of AAV capsids with the potential for highly improved central nervous system transduction efficiency, along with broader presentations showcasing Sangamo’s latest genomic engineering platform evolution.

Global Central Nervous System Partnering 2023: Information on Every Deal Since 2016 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 12, 2023

Global Central Nervous System Partnering 2016 to 2010 provides the full collection of central nervous system disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.

Key Points: 
  • Global Central Nervous System Partnering 2016 to 2010 provides the full collection of central nervous system disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
  • The report takes readers through the comprehensive central nervous system disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering central nervous system deals.
  • Chapter 6 provides a comprehensive directory of all central nervous system partnering deals by specific central nervous system target announced since 2016.
  • Global Central Nervous System Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to central nervous system trends and structure of deals entered into by leading companies worldwide.

José Baselga Research Fund Announces First-Ever Grant to Advance Prion Disease Research

Retrieved on: 
Tuesday, March 21, 2023

The José Baselga Research Fund (JBRF), supported by Alexion, AstraZeneca Rare Disease, today announced the initiation of the Global José Baselga Research Grant (Baselga Grant), an annual $75,000 grant to advance the treatment of prion diseases, a group of rare progressive neurodegenerative disorders.

Key Points: 
  • The José Baselga Research Fund (JBRF), supported by Alexion, AstraZeneca Rare Disease, today announced the initiation of the Global José Baselga Research Grant (Baselga Grant), an annual $75,000 grant to advance the treatment of prion diseases, a group of rare progressive neurodegenerative disorders.
  • JBRF was created by the Baselga family in memory of Dr. José Baselga, a physician-scientist who dedicated his life to the advancement of cancer therapy before passing away two years ago today from Creutzfeldt-Jakob Disease (CJD), an extremely rare, fatal neurodegenerative condition.
  • The Baselga Grant will honor Jose’s legacy and support scientists in the pursuit of understanding, and eradicating, prion diseases such as CJD.
  • The project must have direct applicability and relevance to understanding the pathophysiology or other aspects of prion diseases, developing therapies, or mechanisms for earlier detection of prion disease.

Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases

Retrieved on: 
Tuesday, September 13, 2022

The patents cover methods of treating amyloid lateral sclerosis (ALS), Huntington's disease, and prion diseases by administering buntanetap.

Key Points: 
  • The patents cover methods of treating amyloid lateral sclerosis (ALS), Huntington's disease, and prion diseases by administering buntanetap.
  • A method of treating amyloid lateral sclerosis, a rare progressive neurodegenerative disorder, by administering buntanetap and inhibiting the synthesis of superoxide dismutase protein1 and TDP43.
  • A method of treating Huntington's disease, a rare progressive neurodegenerative disorder, by administering buntanetap and inhibiting the synthesis of Huntingtin protein.
  • For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter .

Blood Emergency: Vitalant Supply Falls by Nearly 50%

Retrieved on: 
Monday, August 22, 2022

SCOTTSDALE, Ariz., Aug. 22, 2022 /PRNewswire/ -- Continued strong patient needs for blood have depleted Vitalant's supply by nearly 50% since the start of summer, creating an emergency shortage across the country.

Key Points: 
  • "Hospitals need people to donate during these critical weeks," said Vitalant Chief Medical and Scientific Officer Dr. Ralph Vassallo.
  • Several patients may experience emergencies, while a planned surgery could suddenly require dozens of units of blood for one patient.
  • Appointments for all blood types are needed to achieve a sufficient four-day supply of all blood types.
  • Vitalant ("Vye-TAL-ent") is the nation's largest independent, nonprofit blood services provider exclusively focused on providing lifesaving blood and comprehensive transfusion medicine services for about 900 hospitals and their patients across the U.S. Every day, Vitalant needs to collect nearly 5,000 blood, platelet and plasma donations to help save lives.

Global Central Nervous System Partnering Deals Directory 2022: Trends, Players and Financials for 1,700+ Deals Signed Since 2015 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 18, 2022

The Global Central Nervous System Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.

Key Points: 
  • The Global Central Nervous System Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.
  • The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.
  • Chapter 6 provides a comprehensive directory of all Central Nervous System partnering deals by specific Central Nervous System target announced since 2015.
  • Global Central Nervous System Partnering 2015 to 2022 includes:
    In Global Central Nervous System Partnering 2015 to 2022, available deals and contracts are listed by:

2021 Global Central Nervous System Partnering Directory: Deal Trends, Players and Financials - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 4, 2022

The "Global Central Nervous System Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Central Nervous System Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • Global Central Nervous System Partnering 2014 to 2010 provides the full collection of Central Nervous System disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
  • The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.
  • In Global Central Nervous System Partnering 2014 to 2021, available deals and contracts are listed by:

Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals

Retrieved on: 
Thursday, November 4, 2021

"This step forward will expand and differentiate Grifols' industry-leading albumin portfolio to benefit patients and bring convenient, flexible container options to our customers."

Key Points: 
  • "This step forward will expand and differentiate Grifols' industry-leading albumin portfolio to benefit patients and bring convenient, flexible container options to our customers."
  • Sustainability was key for Grifols when developing the environmentally friendly ALBUTEIN FlexBag.
  • Both the ALBUTEIN FlexBag flexible container and protective overwrap are latex-free and do not contain polyvinyl chloride (PVC), diethylhexyl phthalate (DEHP) or other plasticizers.
  • The launch of ALBUTEIN FlexBag solidifies Grifols commitment to R+D+i, which has enabled the company to further expand its industry-leading portfolio of plasma-derived medicines for patients and healthcare professionals.